Patents Represented by Attorney, Agent or Law Firm Patricia S. Rocha
  • Patent number: 6667335
    Abstract: Novel imidazole derivatives are disclosed. These compounds have a good affinity to the NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity which makes them key players in mediating processes underlying development of CNS as well as learning and memory formation. These compounds are useful in the control or treatment of diseases mediated by this receptor.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: December 23, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Alanine, Bernd Buettelmann, Marie-Paule Heitz Neidhart, Georg Jaeschke, Emmanuel Pinard, Rene Wyler
  • Patent number: 5356559
    Abstract: Optically active compounds of the formula ##STR1## wherein rings A.sup.1 and A.sup.2 each independently signify pyridine-2,5-diyl, pyrimidine-2,5-diyl or 1,4-phenylene, which is unsubstituted or substituted with at least one of halogen, cyano and/or methyl; R.sup.1 and R.sup.2 each independently represent alkyl with 1 to 18 carbon atoms in which optionally 1 --CH.sub.2 -- group or 2 non-adjacent --CH.sub.2 -- groups is/are replaced by --O--, --COO-- and/or --OOC-- and/or one --CH.sub.2 --CH.sub.2 -- group can be replaced by --CH.dbd.CH--; with the proviso that at least one of the groups R.sup.1 and R.sup.2 must be chiral, liquid crystalline mixtures which contain these compounds and their use for optical and electro-optical purposes.
    Type: Grant
    Filed: July 7, 1992
    Date of Patent: October 18, 1994
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Stephen Kelly
  • Patent number: 5314809
    Abstract: Methods are provided for enhanced specificity and sensitivity of nucleic acid amplification. The methods are simplified nested amplification procedures wherein both inner and outer primer pairs are present in the amplification reaction mixture. According to the methods, the thermocycling profile, as well as the sequences, length, and concentration of amplification primers, is modified to regulate which primers are annealed and extended on the target during any particular amplification cycle. The methods described are particularly suitable in PCR amplifications and have numerous applications in molecular biology, medical diagnostics, and forensics.
    Type: Grant
    Filed: March 10, 1993
    Date of Patent: May 24, 1994
    Assignee: Hoffman-La Roche Inc.
    Inventors: Henry A. Erlich, Russell G. Higuchi
  • Patent number: 5278043
    Abstract: Energy-transfer systems which can be used, inter alia, for measuring distances within or between different molecules are described, comprising derivatives of lumazine and ruthenium, in particular derivatives of DNA or RNA sequences.
    Type: Grant
    Filed: January 22, 1991
    Date of Patent: January 11, 1994
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Wilhelm Bannwarth, Francis Muller
  • Patent number: 5273982
    Abstract: Acetic acid derivatives of formulaH.sub.2 N(NH)C--X--Y--CO--Z--CH(Q.sup.1)COOQ.sup.2 Iand hydrates, solvates and physiologically acceptable salts thereof are useful to inhibit the binding of adhesive proteins to blood platelets and also to inhibit blood platelet aggregation and cell-cell adhesion.
    Type: Grant
    Filed: March 5, 1991
    Date of Patent: December 28, 1993
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Leo Alig, Albrecht Edenhofer, Marcel Muller, Arnold Trzeciak, Thomas Weller
  • Patent number: 5270185
    Abstract: Asymmetrically tailed plasmid primers are provided, each of which comprises a cut, double-stranded DNA plasmid containing a functional origin of replication, at least one functional selection marker gene, a 3' oligo (dT) tail and a 3' oligo (dC) or oligo (dG) tail which is terminated by a phosphate group. Methods for making and using the primers for the highly efficient production of complex cloning libraries and a kit for carrying out the cloning method of the invention are also provided.
    Type: Grant
    Filed: August 12, 1992
    Date of Patent: December 14, 1993
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Robert F. Margolskee
  • Patent number: 5268268
    Abstract: The presence or absence of a nucleic acid sequence of an isolate of HTLVI and/or HTLVII in a sample containing one or more nucleic acids and suspected of containing such sequence can be detected by amplifying the sequence using primers to form extension products as templates and detecting the amplified product if it is present. This may be accomplished by adding a labeled hybridization probe to the amplified product, either free in solution or after immobilization on a solid support.
    Type: Grant
    Filed: August 28, 1991
    Date of Patent: December 7, 1993
    Assignees: Hoffmann-La Roche Inc., Research Foundation of State University of New York
    Inventors: John J. Sninsky, Shirley Y. Kwok, Bernard Poiesz
  • Patent number: 5216148
    Abstract: Described herein are compounds of the formula ##STR1## wherein R.sup.1 signifies hydrogen, lower-alkyl or a cation;R.sup.2 signifies hydrogen, lower-alkyl, lower-alkoxy or halogen;M signifies --CONH-- or --NHCO--;X and Y are each independently selected from the group consisting of >CR.sup.3 R.sup.4 and --CONR.sup.5 --;Z signifies >CR.sup.6 R.sup.7 ;R.sup.3, R.sup.4, R.sup.6 and R.sup.7 are each independently selected from the group consisting of hydrogen and lower-alkyl;R.sup.5 signifies alkyl; andn signifies 0, 1 or 2;provided that at least one of X or Y is --CONR.sup.5 -- which is bonded to the phenyl ring via the N atom.These compounds are useful in the treatment and prophylaxis of neoplasms, dermatoses and aging of the skin.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: June 1, 1993
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Klaus, Peter Mohr
  • Patent number: 5162503
    Abstract: Methods are provided for the purification of interleukin-2 (IL-2) from a wide variety of sources, including synthetic mixtures, culture medium conditioned by natural IL-2 producing cells, and mammalian and bacterial recombinant IL-2 expression systems. The methods of the invention employ IL-2 receptor-affinity adsorbents in which soluble IL-2 receptors have been immobilized on solid supports. Through the use of these affinity adsorbents, highly purified IL-2 can be produced in a single step from bacterial extracts or conditioned medium. The IL-2 thus purified is largely free of aggregated forms, which are often present when other purification methods are used.
    Type: Grant
    Filed: May 19, 1987
    Date of Patent: November 10, 1992
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Pascal Bailon, John E. Smart, David V. Weber
  • Patent number: 5157041
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, cycloalkylcarbonyl, aralkanoyl, aroyl, heterocyclylcarbonyl, alkylsulphonyl, arylsulphonyl, monoaralkylcarbamoyl, cinnamoyl or .alpha.-aralkoxycarbonylaminoalkanoyl and R.sup.2 is hydrogen or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached represent a cyclic imide group of the formula ##STR2## in which P and Q together represent an aromatic system; R.sup.3 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, cyanoalkyl, alkyl- sulphinylalkyl, carbamoylalkyl or alkoxycarbonylalkyl or, when n stands for zero, R.sup.3 can also represent alkylthioalkyl or, when n stands for 1, R.sup.3 can also represent alkylsulphonylalkyl; R.sup.4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; R.sup.5 is hydrogen and R.sup.6 is hydroxy or R.sup.5 and R.sup.6 together represent oxo; R.sup.7 and R.sup.
    Type: Grant
    Filed: June 5, 1989
    Date of Patent: October 20, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Balraj K. Handa, Peter J. Machin, Joseph A. Martin, Sally Redshaw, Gareth J. Thomas
  • Patent number: 5149788
    Abstract: Methods are provided for the purification of interleukin-2 (IL-2) and chimeric proteins containing an IL-2 moiety from a wide variety of sources, including synthetic mixtures, cell culture conditioned medium and mammalian and bacterial recombinant expression systems. The methods of the invention employ IL-2 receptor-affinity adsorbents in which soluble IL-2 receptors have been immobilized on solid supports. Through the use of these affinity adsorbents, highly purified IL-2 and chimeric proteins containing an IL-2 moiety can be produced in a single step from bacterial extracts or conditioned medium. The proteins thus purified are largely free of aggregated forms, which are often present when other purification methods are used.
    Type: Grant
    Filed: October 24, 1988
    Date of Patent: September 22, 1992
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Pascal Bailon, John E. Smart, David V. Weber
  • Patent number: 5142063
    Abstract: The present invention describes novel chiral rhodium-diphosphine complexes having the formula[Rh(X) (Y) (Lp)]owherein X represents a residue of the formula X--COO.sup.- in which Z signifies a group ##STR1## aryl or substituted aryl, wherein R.sup.1, R.sup.2, R.sup.3 =hydrogen, halogen, lower alkyl, aryl-lower alkyl, perfluoro-C.sub.1-20 -alkyl, aryl, substituted aryl, the group --OR.sup.7, --(CH.sub.2).sub.m --COA or AOC--(CF.sub.2).sub.n, with the proviso that at least one of R.sup.1, R.sup.2, and R.sup.3 represents --OR.sup.7, aryl or substituted aryl,R.sup.4, R.sup.5, R.sup.6 =hydrogen, halogen, lower alkyl, aryl-lower alkyl, perfluoro--C.sub.1-20 -alkyl, aryl, substituted aryl, --(CH.sub.2).sub.m --COA or AOC--(CF.sub.2).sub.n,R.sup.7 =hydrogen, lower alkyl, partially or completely halogenated lower alkyl, aryl, substituted aryl or aryl-lower alkyl,A=The residue --OR or NR'.sub.
    Type: Grant
    Filed: November 20, 1990
    Date of Patent: August 25, 1992
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Emil A. Broger, Yvo Crameri
  • Patent number: 5141735
    Abstract: Novel substituted 2-amino-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepines and compositions containing same for treatment and prophylaxis of viral infections, including HIV infections.
    Type: Grant
    Filed: June 18, 1990
    Date of Patent: August 25, 1992
    Assignee: Hoffman-La Roche, Inc.
    Inventors: Anne R. Bellemin, James V. Earley, Ming-Chu Hsu, Steve Yik-Kai Tam
  • Patent number: 5084466
    Abstract: Novel carboxamides and sulfonamides are described having of the formulaR.sup.1 --A--(W).sub.a --X--(CH.sub.2).sub.b --(Y).sub.c --B--Z--COOR (I),in which R.sup.1, A, W, X, Y, B, Z, R, a, b and c are as provided in the description. These compounds are useful in the treatment of thromboses, apoplexy, myocardial infarct, inflammations, arteriosclerosis as well as in the treatment and prevention of tumors. These novel compounds are prepared by eliminating the protective groups in corresponding compounds with protected amidino or guanidino groups.
    Type: Grant
    Filed: January 16, 1990
    Date of Patent: January 28, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Leo Alig, Albrecht Edenhofer, Marcel Muller, Arnold Trzeciak, Thomas Weller
  • Patent number: 5070010
    Abstract: The anti-viral transactivating activity of a test substance is determined by (a) putting both the expression of the Secreted Alkaline Phosphatase gene and the viral transactivator gene under the control of a viral promoter responsive to the action of the transactivator, (b) transfecting cultured mammalian cells with plasmids which contain the gene constructs of (a) and cause cellular production of the transactivating factor and Secreted Alkaline Phosphatase (c) adding the substance to be tested, and (d) determining the amount of Secreted Alkaline Phosphatase produced, whereby inhibition of Secreted Alkaline Phosphatase production correlates with anti-viral transactivating activity.
    Type: Grant
    Filed: October 30, 1989
    Date of Patent: December 3, 1991
    Assignee: Hoffman-La Roche Inc.
    Inventor: Ming Chu Hsu
  • Patent number: 5063162
    Abstract: A process for the isolation of nucleic acids from cell or tissue extracts by precipitating the nucleic acids with a water-soluble ketone, preferably with acetone, optionally in the presence of dimethylformamide or formamide.
    Type: Grant
    Filed: May 9, 1990
    Date of Patent: November 5, 1991
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Hansruedi Kiefer
  • Patent number: 5061788
    Abstract: The invention provides polypeptides which correspond in at least one specific epitope with Plasmodium falciparum merozoite antigen having a molecular weight of about 41,000 Daltons, and a process for their production. The invention further provides immunogenic compositions which contain such a polypeptide and a suitable adjuvant, a DNA sequence which codes for such a polypeptide, replicable microbial vectors which contain such a DNA sequence, microorganisms which contain such a replicable vector and antibodies against a polypeptide of the invention. The invention still further provides processes for the production of the immunogenic compositions, the microorganisms and the antibodies and for the use of the polypeptides and the immunogenic compositions for the immunization of mammals against malaria.
    Type: Grant
    Filed: August 29, 1988
    Date of Patent: October 29, 1991
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Ulrich Certa
  • Patent number: 5036102
    Abstract: A method of treating leukocyte mediated autoimmune and skin diseases using psoralen reagent composition comprising sterile aqueous solutions suitable for extracorporeal administration to blood from a subject being treated by ultraviolet-A photophoresis.
    Type: Grant
    Filed: September 14, 1990
    Date of Patent: July 30, 1991
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria O. Bachynsky, Martin H. Infeld, Richard J. Margolis, Dennis A. Perla
  • Patent number: 5015730
    Abstract: Human fibroblast interferon has been purified to homogeneity by use of a novel procedure combining affinity chromatography and high pressure liquid chromatography (HPLC).
    Type: Grant
    Filed: July 14, 1989
    Date of Patent: May 14, 1991
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Heinz-Jurgen Friesen, Sidney Pestka
  • Patent number: 4999375
    Abstract: Psoralen compositions for extracorporeal administration to blood prior to reinfusion into a subject comprising a sterile aqueous solution of about 0.005 to about 1 mg/ml of a psoralen ethyl alcohol, propylene glycol and water and having a pH from about 2.0 to about 6.0 are disclosed. These compositions are useful for the therapy of a subject being treated by ultraviolet-A photophoresis.
    Type: Grant
    Filed: April 11, 1989
    Date of Patent: March 12, 1991
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria O. Bachynsky, Martin H. Infeld, Richard J. Margolis, Dennis A. Perla